Resmed (RMD) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.

NEW YORK, Nov. 9, 2026 /PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of ResMed Inc. (NYSE: RMD) concerning possible breaches of fiduciary duties. If you are a current shareholder of RM…

ResMed (NYSE: RMD - Get Free Report) and Terumo (OTCMKTS:TRUMY - Get Free Report) are both large-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of …

ResMed, whose devices treat sleep apnea, has dropped on unfounded concerns that weight-loss drugs will replace its treatment. The stock is cheap and worth buying at current prices.…

I present 10 high-quality dividend growth stocks with strong total return potential, screened for robust fundamentals and attractive valuations as of November 2026. Key criteria include Investment Score ≥70, future retur…

ResMed reported that core constant currency revenue grew 7% in the first quarter. Patients on GLP-1 drugs are 11% more likely to start CPAP therapy.…

Although the revenue and EPS for ResMed (RMD) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the …

ResMed's first-quarter fiscal 2027 earnings and revenues top estimates as sustained sleep device demand, productivity gains and gross margin expansion drive growth.…

ResMed NYSE: RMD reported first-quarter fiscal 2027 revenue of $1.4 billion, up 6% from a year earlier on a reported basis and 7% on a core constant-currency basis, as growth in sleep devices, masks and residential care …

ResMed Inc. (RMD) Q1 2027 Earnings Call Transcript…

ResMed (RMD) came out with quarterly earnings of $2.91 per share, beating the Zacks Consensus Estimate of $2.67 per share. This compares to earnings of $2.55 per share a year ago.…

ResMed (NYSE:RMD) reported first-quarter financial results on Thursday. The transcript from the company's first-quarter earnings call has been provided below.…

Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com…

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.…

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for ResMed (RMD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2…

ResMed (RMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.…

RMD heads into Q1 fiscal 2027 earnings with sleep device demand and new product launches supporting growth, while MatrixCare's divestiture weighs on revenues.…

ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

SAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced the U.S. launch of AirTouch F40…

ResMed Inc. (NYSE: RMD - Get Free Report) CEO Michael Farrell sold 4,991 shares of the business's stock in a transaction that occurred on Wednesday, October 7th. The stock was sold at an average price of $226.33, for a t…

SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2027 on Thursday, October 29, 2026, aft…

ResMed (NYSE: RMD) outlined its growth outlook, margin strategy and portfolio plans during a Morgan Stanley discussion, with executives emphasizing demand generation, patient adherence and ongoing product innovation in s…

Engineers Gate Manager LP raised its stake in ResMed Inc. (NYSE: RMD) by 77.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 8,127 sh…

NEW YORK, Sept. 3, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ResMed Inc. ("ResMed" or the "Company") (NYSE: RMD).…

NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ResMed Inc. ("ResMed" or the "Company") (NYSE: RMD). Such investors are advised to contact Danielle Peyton at newac…

SAN DIEGO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Aaron Bloomer, chief financial officer, will attend the 24th Annual Morgan…

SAN DIEGO, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced that Carol Burt will become Lea…
Kept in their own lane. A press release is the company talking, not reporting.
Expected by Jan 27. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

